- Home
- FLYW vs PCRX Comparison
FLYW vs PCRX Comparison
Compare FLYW & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- PCRX
- Stock Information
- Founded
- FLYW 2009
- PCRX 2006
- Country
- FLYW United States
- PCRX United States
- Employees
- FLYW N/A
- PCRX N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- FLYW Technology
- PCRX Health Care
- Exchange
- FLYW Nasdaq
- PCRX Nasdaq
- Market Cap
- FLYW 1.1B
- PCRX 1.2B
- IPO Year
- FLYW 2021
- PCRX 2011
- Fundamental
- Price
- FLYW $10.99
- PCRX $25.58
- Analyst Decision
- FLYW Buy
- PCRX Buy
- Analyst Count
- FLYW 16
- PCRX 9
- Target Price
- FLYW $17.71
- PCRX $30.11
- AVG Volume (30 Days)
- FLYW 3.1M
- PCRX 741.5K
- Earning Date
- FLYW 05-06-2025
- PCRX 05-08-2025
- Dividend Yield
- FLYW N/A
- PCRX N/A
- EPS Growth
- FLYW N/A
- PCRX N/A
- EPS
- FLYW 0.04
- PCRX N/A
- Revenue
- FLYW $511,493,000.00
- PCRX $700,966,000.00
- Revenue This Year
- FLYW $13.82
- PCRX $9.48
- Revenue Next Year
- FLYW $16.22
- PCRX $11.31
- P/E Ratio
- FLYW $309.78
- PCRX N/A
- Revenue Growth
- FLYW 20.97
- PCRX 3.85
- 52 Week Low
- FLYW $8.20
- PCRX $11.16
- 52 Week High
- FLYW $23.40
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- FLYW 69.48
- PCRX 38.94
- Support Level
- FLYW $9.50
- PCRX $25.08
- Resistance Level
- FLYW $11.43
- PCRX $27.34
- Average True Range (ATR)
- FLYW 0.39
- PCRX 1.07
- MACD
- FLYW 0.35
- PCRX -0.28
- Stochastic Oscillator
- FLYW 86.85
- PCRX 13.82
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.